HK1143732A1 - Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571 - Google Patents
Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571Info
- Publication number
- HK1143732A1 HK1143732A1 HK10109892A HK10109892A HK1143732A1 HK 1143732 A1 HK1143732 A1 HK 1143732A1 HK 10109892 A HK10109892 A HK 10109892A HK 10109892 A HK10109892 A HK 10109892A HK 1143732 A1 HK1143732 A1 HK 1143732A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- chronic myelogenous
- myelogenous leukemia
- intolerant
- sti
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31696701P | 2001-09-05 | 2001-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1143732A1 true HK1143732A1 (en) | 2011-01-14 |
Family
ID=23231501
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05101068.0A HK1067562A1 (en) | 2001-09-05 | 2005-02-08 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
HK10109892A HK1143732A1 (en) | 2001-09-05 | 2010-10-19 | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05101068.0A HK1067562A1 (en) | 2001-09-05 | 2005-02-08 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
Country Status (13)
Country | Link |
---|---|
US (1) | US6987103B2 (xx) |
EP (2) | EP2177223B9 (xx) |
JP (2) | JP4794816B2 (xx) |
AT (2) | ATE548041T1 (xx) |
AU (1) | AU2002337410A1 (xx) |
CA (1) | CA2459822C (xx) |
CY (2) | CY1109799T1 (xx) |
DE (1) | DE60234708D1 (xx) |
DK (2) | DK1443933T3 (xx) |
ES (2) | ES2383771T3 (xx) |
HK (2) | HK1067562A1 (xx) |
PT (2) | PT1443933E (xx) |
WO (1) | WO2003020252A2 (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
AU2003291882A1 (en) * | 2002-12-06 | 2004-06-30 | Shire Biochem Inc. | Pharmaceutical combinations and methods for the treatment of leukemia |
US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
ES2400375T3 (es) * | 2006-04-07 | 2013-04-09 | Novartis Ag | Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE |
EP2049096A4 (en) * | 2006-08-02 | 2012-05-09 | Univ South Florida | METHOD FOR TREATING CELLS OF CHRONIC MYELOID LEUKEMIA |
US20090068236A1 (en) * | 2007-04-13 | 2009-03-12 | Chemgenex Pharmaceuticals, Inc. | Oral Cephalotaxine Dosage Forms |
WO2009073885A1 (en) * | 2007-12-07 | 2009-06-11 | Chemgenex Pharmaceuticals, Inc. | Leukemic stem cell ablation |
JP5617175B2 (ja) | 2008-04-17 | 2014-11-05 | 富士電機株式会社 | ワイドバンドギャップ半導体装置とその製造方法 |
AU2012275190B2 (en) * | 2011-06-29 | 2016-05-19 | The Penn State Research Foundation | Compositions, methods and kits for treating leukemia |
KR102004559B1 (ko) | 2011-08-30 | 2019-07-26 | 아스텍스 파마수티컬스, 인크. | 데시타빈 유도체 제제 |
JP6768722B2 (ja) | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
-
2002
- 2002-09-05 DE DE60234708T patent/DE60234708D1/de not_active Expired - Lifetime
- 2002-09-05 EP EP20090172828 patent/EP2177223B9/en not_active Expired - Lifetime
- 2002-09-05 CA CA2459822A patent/CA2459822C/en not_active Expired - Fee Related
- 2002-09-05 ES ES09172828T patent/ES2383771T3/es not_active Expired - Lifetime
- 2002-09-05 JP JP2003524561A patent/JP4794816B2/ja not_active Expired - Fee Related
- 2002-09-05 WO PCT/IB2002/003992 patent/WO2003020252A2/en active Application Filing
- 2002-09-05 PT PT02772653T patent/PT1443933E/pt unknown
- 2002-09-05 AU AU2002337410A patent/AU2002337410A1/en not_active Abandoned
- 2002-09-05 EP EP02772653A patent/EP1443933B1/en not_active Expired - Lifetime
- 2002-09-05 DK DK02772653.8T patent/DK1443933T3/da active
- 2002-09-05 AT AT09172828T patent/ATE548041T1/de active
- 2002-09-05 PT PT09172828T patent/PT2177223E/pt unknown
- 2002-09-05 DK DK09172828.7T patent/DK2177223T3/da active
- 2002-09-05 AT AT02772653T patent/ATE451106T1/de active
- 2002-09-05 ES ES02772653T patent/ES2334774T3/es not_active Expired - Lifetime
-
2003
- 2003-03-27 US US10/397,267 patent/US6987103B2/en active Active
-
2005
- 2005-02-08 HK HK05101068.0A patent/HK1067562A1/xx not_active IP Right Cessation
-
2009
- 2009-02-02 JP JP2009021692A patent/JP2009102408A/ja active Pending
-
2010
- 2010-02-10 CY CY20101100126T patent/CY1109799T1/el unknown
- 2010-10-19 HK HK10109892A patent/HK1143732A1/xx not_active IP Right Cessation
-
2012
- 2012-06-06 CY CY20121100501T patent/CY1112817T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2177223A2 (en) | 2010-04-21 |
EP1443933A2 (en) | 2004-08-11 |
WO2003020252A3 (en) | 2003-06-19 |
US6987103B2 (en) | 2006-01-17 |
CY1109799T1 (el) | 2014-09-10 |
EP2177223B1 (en) | 2012-03-07 |
JP2005508896A (ja) | 2005-04-07 |
US20040019036A1 (en) | 2004-01-29 |
DK2177223T3 (da) | 2012-04-10 |
PT2177223E (pt) | 2012-05-23 |
EP2177223B9 (en) | 2012-10-31 |
ATE548041T1 (de) | 2012-03-15 |
ATE451106T1 (de) | 2009-12-15 |
JP2009102408A (ja) | 2009-05-14 |
HK1067562A1 (en) | 2005-04-15 |
CY1112817T1 (el) | 2016-02-10 |
EP2177223A3 (en) | 2010-05-19 |
JP4794816B2 (ja) | 2011-10-19 |
DE60234708D1 (de) | 2010-01-21 |
ES2334774T3 (es) | 2010-03-16 |
CA2459822A1 (en) | 2003-03-13 |
WO2003020252A2 (en) | 2003-03-13 |
EP1443933B1 (en) | 2009-12-09 |
CA2459822C (en) | 2013-01-29 |
AU2002337410A1 (en) | 2003-03-18 |
PT1443933E (pt) | 2010-01-27 |
DK1443933T3 (da) | 2010-01-25 |
ES2383771T3 (es) | 2012-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1143732A1 (en) | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571 | |
PL1687284T3 (pl) | Inhibitory kinazy p-38 | |
IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
DE60025812D1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
HK1073608A1 (en) | Treatment of alpha-galactosidase a deficiency | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
WO2003105760A3 (en) | PREVENTION AND TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSIS (NAFLD), BY ANTAGONISM OF THE GLUCO-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR (GIP) | |
ZA200407813B (en) | Medicament for preventing and/or treating chronic rejection. | |
BR0215115A (pt) | Tratamento de perda muscular com moduladores de receptores de androgênio seletivos | |
TNSN06182A1 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF | |
ATE505192T1 (de) | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein | |
IL161501A0 (en) | Methods of preventing and treating flavivirus infection in animals | |
HUP0303243A3 (en) | Carbamate compounds for use in preventing and treating bipolar disorder | |
WO2005030151A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2006102611A3 (en) | Therapeutic agents for the treatment of leukemia | |
IS6590A (is) | 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa | |
WO2002070011A3 (en) | Treatment of ppar mediated diseases | |
GB2353473A (en) | Microemulsion preconcentrates containing a piperidine substance P antagonist | |
ATE473001T1 (de) | Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
MXPA03010451A (es) | Nuevos metodos para el tratamiento y prevencion del dolor. | |
WO2003023048A3 (en) | METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180908 |